gastric adenocarcinoma or adenocarcinoma of the gastroesophageal junction (GEJ) and pancreatic adenocarcinoma research hub

A multicentric phase 1/2 trial to evaluate the safety and efficacy of SOT102 as monotherapy and in combination with standard of care treatment in patients with gastric and pancreatic adenocarcinoma

This study is testing a new medicine called SOT102 for stomach and pancreatic cancer. Researchers want to find the safest dose of SOT102, both alone and with standard treatments, and see if it helps shrink tumours. It's an early-stage study, open to adults.